Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.

被引：0
|
作者：
De La Fouchardiere, Christelle
Jiang, Xiaojun
Pissaloux, Daniel
Seigne, Christelle
Wang, Qing
Desseigne, Francoise
Fondrevelle, Marie-Eve
Cassier, Philippe Alexandre
Attignon, Valery
Combaret, Valerie
Perol, David
Tredan, Olivier
Blay, Jean-Yves
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
586
引用
收藏
页数：1
相关论文
共 50 条
  • [21] DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
    Javier Martinez-Useros
    Maria Rodriguez-Remirez
    Aurea Borrero-Palacios
    Irene Moreno
    Arancha Cebrian
    Teresa Gomez del Pulgar
    Laura del Puerto-Nevado
    Ricardo Vega-Bravo
    Alberto Puime-Otin
    Nuria Perez
    Sandra Zazo
    Clara Senin
    Maria J Fernandez-Aceñero
    Maria S Soengas
    Federico Rojo
    Jesus Garcia-Foncillas
    BMC Cancer, 14
  • [22] DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer
    Martinez-Useros, Javier
    Rodriguez-Remirez, Maria
    Borrero-Palacios, Aurea
    Moreno, Irene
    Cebrian, Arancha
    Gomez del Pulgar, Teresa
    del Puerto-Nevado, Laura
    Vega-Bravo, Ricardo
    Puime-Otin, Alberto
    Perez, Nuria
    Zazo, Sandra
    Senin, Clara
    Fernandez-Acenero, Maria J.
    Soengas, Maria S.
    Rojo, Federico
    Garcia-Foncillas, Jesus
    BMC CANCER, 2014, 14
  • [23] Efficacy and safety of irinotecan-based chemotherapy in poor risk patients suffering from metastatic colorectal cancer
    Deptala, A.
    Magon, M.
    Omyla-Staszewska, J.
    Asendrych, A.
    Paluszewska, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
    Lamas, M. J.
    Duran, G.
    Balboa, E.
    Bernardez, B.
    Candamio, S.
    Vidal, Y.
    Mosquera, A.
    Giraldez, J. M.
    Lopez, R.
    Carracedo, A.
    Barros, F.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) : 1591 - 1599
  • [25] aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
    Fujita, Yoshihiko
    Taguri, Masataka
    Yamazaki, Kentaro
    Tsurutani, Junji
    Sakai, Kazuko
    Tsushima, Takahiro
    Nagase, Michitaka
    Tamagawa, Hiroshi
    Ueda, Shinya
    Tamura, Takao
    Tsuji, Yasushi
    Murata, Kohei
    Taira, Koichi
    Denda, Tadamichi
    Moriwaki, Toshikazu
    Funai, Sadao
    Nakajima, Takako Eguchi
    Muro, Kei
    Tsuji, Akihito
    Yoshida, Motoki
    Suyama, Koichi
    Kurimoto, Takuya
    Sugimoto, Naotoshi
    Baba, Eishi
    Seki, Nobuhiko
    Sato, Mikio
    Shimura, Takaya
    Boku, Narikazu
    Hyodo, Ichinosuke
    Yamanaka, Takeharu
    Nishio, Kazuto
    ONCOLOGIST, 2019, 24 (03): : 327 - 337
  • [26] Complete response of a metastatic gastroesophageal adenocarcinoma on irinotecan-based chemotherapy in a dialysis patient
    Verwimp, J.
    Geurs, F.
    Ponette, S.
    Ponette, J.
    Martens, J.
    Bulte, K.
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2010, 3 : 61 - 64
  • [27] The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
    M. J. Lamas
    G. Duran
    E. Balboa
    B. Bernardez
    S. Candamio
    Y. Vidal
    A. Mosquera
    J. M. Giraldez
    R. Lopez
    A. Carracedo
    F. Barros
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1591 - 1599
  • [28] A multicenter exploratory study of irinotecan-based chemotherapy on UGT1A1 polymorphisms for patients with colorectal cancer.
    Chikakiyo, Motoya
    Sato, Hirohiko
    Kurita, Nobuhiro
    Iwata, Takashi
    Yoshikawa, Kozo
    Kashihara, Hideya
    Mikami, Chie
    Matsumoto, Noriko
    Eto, Shohei
    Shimada, Mitsuo
    Hotchi, Masanori
    Okitsu, Hiroshi
    Sonaka, Yasuhide
    Yoshida, Sadahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
    Iwasa, Satoru
    Muro, Kei
    Morita, Satoshi
    Park, Young Suk
    Nakamura, Masato
    Kotaka, Masahito
    Nishina, Tomohiro
    Matsuoka, Hiroshi
    Ahn, Joong Bae
    Lee, Keun-Wook
    Hong, Yong Sang
    Han, Sae Won
    Cho, Sang-Hee
    Zhang, Dong-Sheng
    Fang, Wei-Jia
    Bai, Li
    Yuan, Xiang-Lin
    Yuan, Ying
    Yamada, Yasuhide
    Sakamoto, Junichi
    Kim, Tae Won
    CANCER SCIENCE, 2021, 112 (11) : 4669 - 4678
  • [30] Effects of MTHFR Genetic Polymorphisms on Toxicity and Clinical Response of Irinotecan-Based Chemotherapy in Patients with Colorectal Cancer
    Li, Ping
    Chen, Quan
    Wang, Ya-Di
    Ha, Min-Wen
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2014, 18 (05) : 313 - 322
12345